BridgeBio (BBIO): Proposed sale of 50,000 shares worth $2.4M

BridgeBio Pharma filed a Form 144 reporting a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,400,000.

Rhea-AI Filing Summary

BridgeBio Pharma filed a Form 144 reporting a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,400,000. The filing shows 191,168,504 shares outstanding.

The 50,000 shares to be sold were acquired on 07/01/2019 as founders' shares from the issuer and paid for in cash. The filing also discloses three sales by Charles J Homcy on 08/08/2025 totaling 250,000 common shares with gross proceeds of $6,907,905, $2,302,295 and $2,302,220 (combined $11,512,420).

Positive

• Transaction details are fully disclosed, including broker, acquisition date, origin as founders' shares, and payment method (cash).
• Recent sale proceeds are itemized, providing clear dollar amounts and dates for investor review.

Negative

• Significant insider monetization occurred: three sales on 08/08/2025 totaling 250,000 shares for $11,512,420 in gross proceeds.
• An additional planned sale of 50,000 shares (aggregate market value $2.4M) is disclosed, which increases near-term share supply from related parties.

Insights

Securities Analyst

TL;DR: Recent large share dispositions and an additional planned sale are disclosed; impact appears transactional rather than company-specific.

The filing documents a proposed sale of 50,000 shares valued at $2.4M and prior sales totaling 250,000 shares for approximately $11.51M. These amounts are explicit and sizeable in dollar terms but represent small percentages of the reported 191.17M shares outstanding. From a market-impact perspective, the disclosure signals notable insider monetization in the near term; however, the filing contains no operational or financial performance details to suggest a material change to the companys fundamentals.

Corporate Governance Expert

TL;DR: The filer documents founder-origin shares and multiple recent sales; disclosure is complete but raises typical governance questions about insider liquidity.

The record shows the shares to be sold were acquired as founders' shares on 07/01/2019 and paid for in cash, indicating long-held positions being liquidated. The filing names Charles J Homcy as the seller for recent transactions on 08/08/2025. This Form 144 provides required transparency under Rule 144; it does not include commentary on any trading plans or other governance arrangements that might contextualize the sales.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the BridgeBio (BBIO) Form 144 report?

The Form 144 reports a proposed sale of 50,000 common shares valued at $2,400,000 through Morgan Stanley Smith Barney LLC on NASDAQ.

Who sold shares and when were recent sales made?

The filing lists Charles J Homcy as having sold shares on 08/08/2025, with three transactions totaling 250,000 common shares.

How much did the recent sales generate in proceeds?

The three sales on 08/08/2025 produced gross proceeds of $6,907,905, $2,302,295, and $2,302,220, totaling $11,512,420.

When and how were the shares to be sold acquired?

The 50,000 shares to be sold were acquired on 07/01/2019 as founders' shares from the issuer, and payment was made in cash.

How many BridgeBio shares are outstanding per the filing?

The filing reports 191,168,504 shares outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2025 - 04:17 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001192591
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BRIDGEBIO PHARMA, INC.
SEC File Number	001-38959
Address of Issuer	3160 Porter Drive Suite 250 Palo Alto CALIFORNIA 94304
Phone	(650) 391-9740
Name of Person for Whose Account the Securities are To Be Sold	CHARLES J HOMCY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	50000	2400000.00	191168504	08/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/01/2019	Founders Shares	ISSUER			50000	07/01/2019	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
CHARLES J HOMCY 3160 Porter Drive Suite 250 Palo Alto CA 94304	Common	08/08/2025	150000	6907905.00
CHARLES J HOMCY 3160 Porter Drive Suite 250 Palo Alto CA 94304	Common	08/08/2025	50000	2302295.00
CHARLES J HOMCY 3160 Porter Drive Suite 250 Palo Alto CA 94304	Common	08/08/2025	50000	2302220.00

144: Remarks and Signature

Remarks
Date of Notice	08/11/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/08/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Charles Jude Homcy
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)